Literature DB >> 23105143

Tumor-associated macrophages promote invasion while retaining Fc-dependent anti-tumor function.

Katharine D Grugan1, Francis L McCabe, Michelle Kinder, Allison R Greenplate, Benjamin C Harman, Jason E Ekert, Nico van Rooijen, G Mark Anderson, Jeffrey A Nemeth, William R Strohl, Robert E Jordan, Randall J Brezski.   

Abstract

Tumor-associated macrophages (TAMs) have been shown to promote tumor progression, and increased TAM infiltration often correlates with poor prognosis. However, questions remain regarding the phenotype of macrophages within the tumor and their role in mAb-dependent cytotoxicity. This study demonstrates that whereas TAMs have protumor properties, they maintain Fc-dependent anti-tumor function. CD11b(+)CD14(+) TAMs isolated from primary human breast tumors expressed activating FcγRs. To model breast cancer TAMs in vitro, conditioned medium from breast cancer cells was used to drive human peripheral monocyte differentiation into macrophages. Tumor-conditioned macrophages were compared with in vitro derived M1 and M2a macrophages and were found to promote tumor cell invasion and express M2a markers, confirming their protumor potential. However, unlike M2a macrophages, tumor-conditioned macrophages expressed FcγRs and phagocytosed tumor cells in the presence of a tumor Ag-targeting mAb, unmasking an underappreciated tumoricidal capacity of TAMs. In vivo macrophage depletion reduced the efficacy of anti-CD142 against MDA-MB-231 xenograft growth and metastasis in SCID/beige mice, implicating a critical role for macrophages in Fc-dependent cell killing. M-CSF was identified in tumor-conditioned media and shown to be capable of differentiating macrophages with both pro- and anti-tumor properties. These results highlight the plasticity of TAMs, which are capable of promoting tumor progression and invasion while still retaining tumoricidal function in the presence of tumor-targeting mAbs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23105143     DOI: 10.4049/jimmunol.1201889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

1.  Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.

Authors:  Ahmed T Kurdi; Siobhan V Glavey; Natalie A Bezman; Amy Jhatakia; Jennifer L Guerriero; Salomon Manier; Michele Moschetta; Yuji Mishima; Aldo Roccaro; Alexandre Detappe; Chia-Jen Liu; Antonio Sacco; Daisy Huynh; Yu-Tzu Tai; Michael D Robbins; Jamil Azzi; Irene M Ghobrial
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

2.  A new inflammatory role for p53 in human macrophages.

Authors:  Julie M Lowe; Daniel Menendez; Michael B Fessler
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 3.  Progress in tumor-associated macrophage (TAM)-targeted therapeutics.

Authors:  Chayanon Ngambenjawong; Heather H Gustafson; Suzie H Pun
Journal:  Adv Drug Deliv Rev       Date:  2017-04-25       Impact factor: 15.470

4.  Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CA.

Authors:  Juan Carlos Almagro; Gary L Gilliland; Felix Breden; Jamie K Scott; Devin Sok; Matthias Pauthner; Janice M Reichert; Gustavo Helguera; Raiees Andrabi; Robert Mabry; Mathieu Bléry; James E Voss; Juha Laurén; Lubna Abuqayyas; Stefan Barghorn; Eshel Ben-Jacob; James E Crowe; James S Huston; Stephen Albert Johnston; Eric Krauland; Fridtjof Lund-Johansen; Wayne A Marasco; Paul W H I Parren; Kai Y Xu
Journal:  MAbs       Date:  2014-03-03       Impact factor: 5.857

Review 5.  Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).

Authors:  Olga V Zhukova; Tatiana F Kovaleva; Evgenia V Arkhipova; Sergey A Ryabov; Irina V Mukhina
Journal:  Biomed Rep       Date:  2020-08-28

Review 6.  Spatio-temporal modeling and live-cell imaging of proteolysis in the 4D microenvironment of breast cancer.

Authors:  Kyungmin Ji; Mansoureh Sameni; Kingsley Osuala; Kamiar Moin; Raymond R Mattingly; Bonnie F Sloane
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

7.  GDF15 derived from both tumor-associated macrophages and esophageal squamous cell carcinomas contributes to tumor progression via Akt and Erk pathways.

Authors:  Naoki Urakawa; Soken Utsunomiya; Mari Nishio; Manabu Shigeoka; Nobuhisa Takase; Noriaki Arai; Yoshihiro Kakeji; Yu-ichiro Koma; Hiroshi Yokozaki
Journal:  Lab Invest       Date:  2015-03-02       Impact factor: 5.662

8.  Macrophages eliminate circulating tumor cells after monoclonal antibody therapy.

Authors:  Nuray Gül; Liane Babes; Kerstin Siegmund; Rianne Korthouwer; Marijn Bögels; Rens Braster; Gestur Vidarsson; Timo L M ten Hagen; Paul Kubes; Marjolein van Egmond
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

Review 9.  The divergent roles of macrophages in solid organ transplantation.

Authors:  Sahar Salehi; Elaine F Reed
Journal:  Curr Opin Organ Transplant       Date:  2015-08       Impact factor: 2.640

10.  Engineered protease-resistant antibodies with selectable cell-killing functions.

Authors:  Michelle Kinder; Allison R Greenplate; Katharine D Grugan; Keri L Soring; Katharine A Heeringa; Stephen G McCarthy; Gregory Bannish; Meredith Perpetua; Frank Lynch; Robert E Jordan; William R Strohl; Randall J Brezski
Journal:  J Biol Chem       Date:  2013-08-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.